Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. develops therapeutics for Alzheimer's disease and metabolic disorders as a clinical-stage biotechnology company. News about IGC Pharma commonly centers on IGC-AD1, its cannabinoid-based lead asset in the CALMA Phase 2 trial for agitation in Alzheimer's dementia, along with pipeline programs such as TGR-63, IGC-1C and IGC-M3 targeting amyloid plaques, tau pathways, neuroinflammation and related neurodegeneration biology.
Company updates also cover the use of artificial intelligence in drug discovery and clinical-trial operations, including the Agentic Harmonization Assistant platform for biomedical data harmonization. Other recurring developments include clinical-site expansion, caregiver and patient-engagement initiatives, psilocybin research authorization in Colombia, patent activity and financial reporting.
IGC Pharma (NYSE American: IGC) has announced its participation in a fireside chat hosted by Ascendiant Capital Markets scheduled for January 23, 2025, at 1:00 pm ET. CEO Ram Mukunda and CCO Claudia Grimaldi will lead the discussion.
The management team will provide updates on several key areas including:
- Recent progress in the company's Alzheimer's pipeline
- Strategic expansion into metabolic disorders
- Integration of artificial intelligence in drug discovery
The discussion will also cover upcoming milestones, including:
- New clinical trial launches
- Preclinical developments
- Efforts to expand their addressable market in Alzheimer's disease and weight loss therapies
IGC Pharma has officially named its Phase 2 trial for Alzheimer's agitation as CALMA (Calming Agitation in Alzheimer's). The trial addresses agitation, a condition affecting up to 76% of the 55 million Alzheimer's patients worldwide. The company has implemented an innovative recruitment strategy using geofencing technology and digital outreach through social media platforms.
The pilot recruitment campaign at select trial sites achieved a 200-300% increase in enrollment at a relatively low cost per lead. IGC Pharma is now expanding this strategy across all trial locations in the USA and Canada, targeting individuals within a 15-25-mile radius of clinical sites. The company aims to complete enrollment and the CALMA trial in the second half of 2025.
IGC Pharma announced its participation in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 from January 13-16, 2025. The company's management team will be available for both in-person and virtual meetings with registered investors and pharmaceutical companies. During these one-on-one meetings, they will present their business strategy, recent partnerships, achievements, and anticipated milestones. IGC will also host separate one-on-one meetings in San Francisco during JPM Week.
IGC Pharma announced an expansion of its clinical research program for IGC-AD1, an investigational Alzheimer's treatment. Building on Phase 2 interim results showing reduced agitation and cognitive improvement, the company plans to initiate new trials in 2025 to evaluate IGC-AD1's potential as a disease-modifying therapy. Preclinical studies demonstrated approximately 50% improvement in spatial memory and 20% reduction in amyloid aggregation. The ongoing 146-patient Phase 2 trial has administered over 1,000 doses with no serious adverse events reported, with comprehensive data expected in 2025.
IGC Pharma has announced additional interim results from its Phase 2 clinical trial of IGC-AD1 for Alzheimer's treatment. The active treatment group showed an average 8% improvement in cognitive function on the Mini-Mental State Examination over six weeks, while the placebo group showed no improvement. The trial primarily focuses on agitation reduction, where IGC-AD1 demonstrated significant improvements compared to placebo within two weeks. These results align with preclinical data showing 20% reduction in amyloid plaque aggregation and 50% improvement in spatial memory in mouse models. No serious adverse events were reported during the trial.
IGC Pharma reported Q2 FY2025 results with significant pipeline developments in Alzheimer's treatments. Revenue grew 42% to $412,000, while net loss decreased to $1.7 million ($0.02 per share) from $2.5 million ($0.05 per share) in Q2 FY2024. The quarter highlighted progress in multiple compounds: TGR-63 demonstrated blood-brain barrier crossing ability, IGC-1A was identified as a potential GLP-1 agonist through AI modeling, IGC-1C showed promising preclinical results targeting tau protein, and IGC-AD1 advanced as a dual-action disease-modifying therapy. SG&A expenses decreased 25% to $1 million, and R&D expenses reduced 28% to $917,000.
IGC Pharma announces the publication of an interview with CEO Ram Mukunda in the IMS Spotlight Series. The interview highlights the company's strategic expansion into metabolic and neurological markets, focusing on GLP-1 agonists for both Alzheimer's and weight loss therapies. Mukunda discusses updates on IGC-AD1, their lead candidate currently in Phase 2 trials for treating agitation in Alzheimer's dementia, which is advancing toward additional trials for potential disease-modifying treatment. The company emphasizes its use of artificial intelligence to diversify its pipeline across neurodegenerative and metabolic disorders.
IGC Pharma (NYSE American:IGC) has announced the enrollment of patients at Baycrest Academy for Research and Education in Toronto, Canada, for its ongoing Phase 2 trial of IGC-AD1, a treatment for agitation in Alzheimer's dementia. IGC-AD1 is a partial CB1 receptor agonist with anti-neuroinflammatory properties, targeting key pathways involved in Alzheimer's disease pathology. The trial expansion to Canada follows approval from Health Canada.
Dr. Howard Chertkow, Chair of Cognitive Neurology and Innovation at Baycrest, emphasized the importance of this study in addressing behavioral symptoms of Alzheimer's. The trial will enroll 164 patients, with half receiving IGC-AD1 and half receiving a placebo. IGC Pharma currently has 12 U.S. trial sites under contract and plans to add more in Canada to increase population diversity.
IGC Pharma, Inc. (NYSE American:IGC) has won two awards in Phase 1 of the National Institute on Aging's PREPARE Challenge, which aims to accelerate the development of tools for Alzheimer's and related dementias. The company's entry, using the Mexican Health and Aging Study database, won the Disproportionate Impact prize and placed third overall.
IGC is developing AI and deep learning models to predict cognitive decline up to 20 years before symptoms appear, potentially improving patient outcomes and reducing healthcare costs. CEO Ram Mukunda stated that these recognitions underscore IGC's leadership in AI research for Alzheimer's disease prediction and could help address the projected $1 trillion economic burden on the U.S. healthcare system.
IGC Pharma (NYSE American: IGC) has announced promising preclinical data for IGC-AD1, its potential Alzheimer's disease treatment. The drug demonstrates the ability to modify tau pathology and improve spatial memory, building on previous findings of amyloid plaque reduction. Key results include:
1. 10% reduction in the ratio of phosphorylated tau to total tau
2. 35% reduction in GSK3 enzyme expression
3. 50% faster improvement in spatial memory tests
IGC-AD1 is currently in a Phase 2 clinical trial for agitation in Alzheimer's, with over 1,000 oral doses administered and no dose-limiting adverse events observed. The company aims to position IGC-AD1 for two large indications: agitation in Alzheimer's and as a disease-modifying anti-amyloid/anti-tangle treatment.